ICD E76.22ORPHA:581MPS III

Sanfilippo Syndrome

Sanfilippo syndrome (MPS III) is a rare lysosomal storage disorder caused by enzyme deficiencies that result in heparan sulfate accumulation in cells. It causes progressive neurodegeneration, intellectual regression, and behaviour problems in childhood. Australian families have been pivotal in advocating for gene therapy research.

326
Articles
36
Trials (3 AU)
Updated
25 March 2026
Loading...

Common Questions

What is Sanfilippo Syndrome?

Sanfilippo syndrome (MPS III) is a rare lysosomal storage disorder caused by enzyme deficiencies that result in heparan sulfate accumulation in cells. It causes progressive neurodegeneration, intellectual regression, and behaviour problems in childhood. Australian families have been pivotal in advocating for gene therapy research.

How many clinical trials are available for Sanfilippo Syndrome?

RareWays currently indexes 36 clinical trials for Sanfilippo Syndrome, of which 7 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.

Where does the research data for Sanfilippo Syndrome come from?

RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.

Get research updates

Monthly email when new findings are published for Sanfilippo Syndrome.

No spam. Unsubscribe any time. Not medical advice.

This information is for general awareness only.

For guidance specific to your situation, please speak with your healthcare team.